Block listing Interim Review
1 June 2020 15:00 BST
Block Listing Six Monthly Return
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 1 June 2020
|Name of applicant:||ASTRAZENECA PLC|
|Name of scheme:||ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME|
|Period of return:||From:||1 December 2019||To:||31 May 2020|
|Balance of unallotted securities under scheme(s) from previous return:||1,111,666|
|Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):||0|
|Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):||348,131|
|Equals: Balance under scheme(s) not yet issued/allotted at end of period:||763,535|
|Name of contact:||CAMILLA JOHNSTONE|
|Telephone number of contact:||020 3749 5000|
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.